MagBio Genomics, Inc. Launches a Novel System for Collection, Stabilization, Transport, Storage and Isolation of Circulating Cell-Free DNA
Blood STASIS 21-ccfDNA improves and reduces cost of whole blood sample handling as well as workflow convenience for cancer genomic research
Gaithersburg, MD, February 15, 2017 (Newswire.com) - MagBio Genomics Inc. announces the launch of its new Blood STASISTM 21- ccfDNA tube for venous whole blood collection and room temperature stabilization of circulating cell-free DNA (ccfDNA).
The Blood STASIS 21-ccfDNA is a direct draw whole blood collection system that contains a proprietary reagent that prevents post-collection release of genomic DNA from white blood cells, resulting in efficient and accurate recovery of ccfDNA with minimal genomic DNA (gDNA) contamination leading to more informative and quality data.
Other blood stabilization systems contain potential formaldehyde-releasing compounds, making them unsuitable for many liquid biopsy applications, and limiting room temperature blood stabilization to only 10 days. The Blood STASIS 21-ccfDNA stabilization reagent is compatible with almost all genomic related assays and allows room temperature transport and storage of blood for 21 days, and epithelial cells for 8 days. Additionally the Blood STASIS 21-ccfDNA tube is plastic, making it less susceptible to breakage. These unique features of Magbio’s new Blood STASIS 21-ccfDNA tube significantly expand the range of liquid biopsy applications such as non-invasive prenatal testing (NIPT) and cancer genomic assays and improve operational efficiency, reduce costs, and enhance outreach for receiving samples on local and international levels.
In combination with MagBio’s cfKapture 21 (the only ccfDNA isolation kit on the market featuring a plasma stabilization reagent that allows separated plasma to remain room temperature stable up to 21 days without degradation of plasma ccfDNA), Blood STASIS 21-ccfDNA tube offers an efficient and cost effective solution to the initial steps in the ccfDNA analysis work flow including blood collection, stabilization, transport, storage and isolation of high quality ccfDNA.
Blood STASISTM 21-ccfDNA Tube is for Research Use Only (RUO).
“Successful use of whole blood samples as liquid biopsies for cancer genomic research and Non Invasive Prenatal Testing (NIPT) is dependent on several factors such as convenience, efficiency of blood sample handling, and quality of recovered ccfDNA. The choice of sample stabilization buffer also plays a key role, in that it must be compatible with a full range of liquid biopsy applications for genomic assays.
Currently, whole blood sample collection tubes can stabilize ccfDNA for only a few days and within a limited temperature range which limits the ability to acquire and manage samples on a truly international scale. Our Blood STASIS 21 tube enables whole sample collection, safe transport, and storage at temperatures up to 32oC while maintaining integrity of ccfDNA for 21 days. These features break down the barrier of sample degradation caused by extended transit times and fluctuating temperatures and allow researchers to freely collaborate globally for ccfDNA analysis in NIPT and cancer research,” Hyacinth Ntchobo, Ph.D. – CEO MagBio Genomics.
About MagBio Genomics, Inc.
MagBio Genomics, Inc. is an emerging biotechnology company based in Gaithersburg Maryland, USA that develops and commercializes magnetic bead-based products for nucleic acids isolation including biomarkers as tools for liquid biopsy. Our current focus encompasses products that allow both safeguarding integrity of bio-samples and efficient isolation of circulating biomarkers from biological samples for human genetic research including cancer studies and non-invasive prenatal testing (NIPT). Our core platform allows efficiency in the nucleic acids sequencing methods including Sanger and Next Generation Sequencing (NGS) in both manual and automated work flow. MagBio Genomics serve customers including Academic and Private Genomics Research Institutions, as well as clinical genomic research across the Globe.
Source: MagBio Genomics, Inc.